Hu Xuekai, Wei Jiayun, Liu Pinyan, Zheng Qiuxia, Zhang Yue, Zhang Qichen, Yao Jia, Ni Jingman
School of Pharmacy, Lanzhou University, Lanzhou, 730000, China.
The First school of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Cell Biosci. 2024 Aug 27;14(1):107. doi: 10.1186/s13578-024-01287-5.
Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine.
原发性肝癌（PLC）是全球最常见的恶性胃肠道肿瘤之一。受肝移植供体短缺和肿瘤异质性的限制，肝癌患者缺乏有效的治疗选择，这导致疾病迅速进展和转移。目前，PLC的临床前模型与临床实际情况存在差距，在反映疾病进展和药物治疗效果方面存在局限性。类器官是体外三维培养的临床前模型，具有高度的异质性，保留了原发性肿瘤的组织形态学和基因组特征。肝癌类器官已广泛应用于药物筛选、新靶点发现和精准医学；因此，它是研究PLC的一种很有前景的工具。在这里，我们总结了肝癌类器官的研究进展及其作为疾病模型的潜在应用。这篇综述全面介绍了这项新兴技术，并为研究人员在精准医学领域的探索提供了新思路。
